Read by QxMD icon Read

breast cancers

Raymond Barnhill, Peter Vermeulen, Sofie Daelemans, Pieter-Jan van Dam, Sergio Roman-Roman, Vincent Servois, Ilse Hurbain, Sophie Gardrat, Graça Raposa, Nicolas André, Rémi Dendale, Gaëlle Pierron, Laurence Desjardins, Nathalie Cassoux, Sophie Piperno-Neumann, Pascale Mariani, Claire Lugassy
Up to 50% of uveal melanomas (UM) metastasize to the liver within 10 years of diagnosis, and these almost always prove rapidly fatal. Since histopathological growth patterns (HGP) of liver metastases of the replacement and desmoplastic type, particularly from colon and breast carcinoma, may import valuable biological and prognostic information, we have studied HGP in a series of 41 UM liver metastases originating from 41 patients from the period 2006-2017. Twenty patients underwent enucleation while 21 had radiation therapy...
June 19, 2018: Journal of Pathology. Clinical Research
Shanshan Wu, Wanjiao Li, Qiongxiao Zhang, Shuting Li, Lizi Wang
AIM: To compare peripheral arm ports versus central chest ports in complication rates. BACKGROUND: Late complications of arm ports versus chest ports, including catheter-related infection, venous thrombosis and catheter obstruction, remain controversial. DESIGN: A meta-analysis conducted following the Cochrane handbook. DATA SOURCES: Studies published between 1950 - August 2017 were searched through Pubmed, Embase, Web of science and Cochrane library...
June 19, 2018: Journal of Advanced Nursing
Y-T Fu, H-B Zheng, D-Q Zhang, L Zhou, H Sun
OBJECTIVE: To explore the effects of microRNA-1266 (miR-1266) on metastasis and growth in papillary thyroid carcinoma cells and to provide therapeutic targets for papillary thyroid carcinoma. PATIENTS AND METHODS: By quantitative Real-time polymerase chain reaction (PCR), miR-1266 expression level in 38 pairs of papillary thyroid carcinoma tissues and three breast cancer-derived cell lines was examined. After transfection with miR-1266 mimics, the effects of miR-1266 over-expression on cell proliferation, invasion and migration were analyzed...
June 2018: European Review for Medical and Pharmacological Sciences
(no author information available yet)
No abstract text is available yet for this article.
June 1, 2018: Journal of the National Cancer Institute
Susanne Horn, Sonia Leonardelli, Antje Sucker, Dirk Schadendorf, Klaus G Griewank, Annette Paschen
Poor clinical responses to checkpoint blockade with anti-CTLA-4 and anti-PD-1 antibodies in melanoma have recently been associated with acquired IFNγ resistance that protects tumor cells from the antiproliferative and pro-apoptotic cytokine activity. IFNγ-resistant melanoma cells very often lack functional expression of the IFNγ signaling pathway gene JAK2 due to gene deletions or inactivating gene mutations. Analyzing melanoma cell lines (n = 46, applying next-generation targeted sequencing and single nucleotide polymorphism arrays) as well as available genomic data sets from The Cancer Genome Atlas (TCGA) tumor tissue samples (cutaneous melanoma n = 367, lung squamous cell carcinoma n = 501, bladder urothelial carcinoma n = 408, breast invasive carcinoma n = 768, colorectal adenocarcinoma n = 257), we demonstrate that the frequent chromosomal losses of the tumor suppressor CDKN2A in melanoma and other tumor entities enhance the susceptibility to IFNγ resistance by concomitant deletion of the JAK2 gene (odds ratio = 223...
June 1, 2018: Journal of the National Cancer Institute
Antonia K Roseweir, Lindsay Bennett, Ashley Dickson, Kelvin Cheng, Mary-Anne Quintayo, Jane Bayani, Donald C McMillan, Paul G Horgan, Cornelis J H van de Velde, Caroline Seynaeve, Annette Hasenburg, Dirk G Kieback, Christos Markopoulos, Luc Y Dirix, Daniel W Rea, Elizabeth A Mallon, John M S Bartlett, Joanne Edwards
Background: Aromatase inhibitors improve disease-free survival compared with tamoxifen in postmenopausal women with hormone receptor-positive breast cancer. The Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial compared exemestane monotherapy with sequential therapy of tamoxifen followed by exemestane. The trial failed to show a statistically significant difference between treatment arms. A robust translational program was established to investigate predictive biomarkers. Methods: A tissue microarray was retrospectively constructed using a subset of patient tissues (n = 4631) from the TEAM trial (n = 9766)...
June 1, 2018: Journal of the National Cancer Institute
N Brusselaers, R M Tamimi, P Konings, B Rosner, H-O Adami, J Lagergren
Background: There are considerable knowledge gaps concerning different estrogen and progestin formulations, regimens, and modes of administration of menopausal hormone therapy and the risk of breast cancer. Our objective was to assess the different treatment options for menopausal hormone therapy and the risk of breast cancer. Patients and methods: This Swedish prospective nationwide cohort study included all women who received ≥1 hormone therapy prescription during the study period 2005-2012 (290,186 ever-users), group-level matched (1:3) to 870,165 never-users; respectively 6,376 (2...
June 18, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
M Diossy, L Reiniger, Z Sztupinszki, M Krzystanek, K M Timms, C Neff, C Solimeno, D Pruss, A C Eklund, E Tóth, O Kiss, O Rusz, G Cserni, T Zombori, B Székely, J Tímár, I Csabai, Z Szallasi
Background: Based on its mechanism of action, PARP inhibitor therapy is expected to benefit mainly tumor cases with homologous recombination deficiency (HRD). Therefore, identification of tumor types with increased HRD is important for the optimal use of this class of therapeutic agents. HRD levels can be estimated using various mutational signatures from next generation sequencing data and we used this approach to determine whether breast cancer brain metastases show altered levels of HRD scores relative to their corresponding primary tumor...
June 18, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Elisabetta Avitabile, Davide Bedognetti, Gianni Ciofani, Alberto Bianco, Lucia Gemma Delogu
In this review we provide a broad overview on the use of nanotechnology for the fight against breast cancer (BC). Nowadays, detection, diagnosis, treatment, and prevention may be possible thanks to the application of nanotechnology to clinical practice. Taking into consideration the different forms of BC and the disease status, nanomaterials can be designed to meet the most forefront objectives of modern therapy and diagnosis. We have analyzed in detail three main groups of nanomaterial applications for BC treatment and diagnosis...
June 19, 2018: Nanoscale
Benjamin Woodhams, Laura Ansel-Bollepalli, Jakub Surmacki, Helena Knowles, Laura Maggini, Michael de Volder, Mete Atatüre, Sarah Bohndiek
Nanodiamonds have demonstrated potential as powerful sensors in biomedicine, however, their translation into routine use requires a comprehensive understanding of their effect on the biological system being interrogated. Under normal fabrication processes, nanodiamonds are produced with a graphitic carbon shell, but are often oxidized in order to modify their surface chemistry for targeting to specific cellular compartments. Here, we assessed the biological impact of this purification process, considering cellular proliferation, uptake, and oxidative stress for graphitic and oxidized nanodiamond surfaces...
June 19, 2018: Nanoscale
Hayley C Oligane, Wendie A Berg, Andriy I Bandos, Sue S Chen, Sahand Sohrabi, Maria Anello, Margarita L Zuley
Purpose To determine rate of malignancy at stereotactic biopsy of amorphous calcifications with different distributions using current imaging, clinical, and histopathologic criteria. Materials and Methods From January 2009 to September 2013, this retrospective study reviewed a large set of stereotactic biopsies to identify amorphous calcifications and their clinical, imaging, and histopathologic characteristics. Calcification distribution was correlated with malignancy rate after adjusting for known risk factors using logistic regression...
June 19, 2018: Radiology
Vo Thi Thuong Lan, Ho Van Son, Vu Lan Trang, Nguyen Thu Trang, Nguyen Thi Phuong, Nguyen Linh Toan, Pham Anh Thuy Duong
The three genes encoding small non‑coding microRNA (miR)34a, MIR34b and MIR34c act as tumor‑suppressor genes. Their aberrant expressions regulated by DNA methylation have been frequently found in various types of cancer. In the present study, the DNA promoter methylation profiles of the MIR34 gene family were analyzed using the methylation specific polymerase chain reaction in order to clarify their association with breast and lung cancer, non‑cancerous or normal adjacent tissues. The methylation frequency of MIR34a was significantly higher in breast cancer (49...
June 18, 2018: Molecular Medicine Reports
Yanan Sun, Fangyan Jiang, Yuemei Pan, Xinming Chen, Jirong Chen, Yu Wang, Xueqing Zheng, Jiali Zhang
X‑box‑binding protein 1 (XBP1) contributes to various types of cancer including breast, bladder cancer and esophageal squamous cell carcinoma. The aim of the study was to examine the metastatic role of XBP1 in oral squamous cell carcinoma (OSCC), and identify possible downstream molecules. Immunohistochemical staining was conducted on tissue microarrays comprising 96 OSCC cases to determine the expression level of XBP1 and analyze its association with metastasis, clinicopathological characteristics and survival prognosis...
June 18, 2018: Oncology Reports
Wei Cai, Yong Xu, Jian Yin, Wenshan Zuo, Zhen Su
Recently, microRNA (miR)‑590‑5p has been shown to inhibit tumorigenesis in colorectal and breast cancer; however, its function in osteosarcoma (OS) requires further investigation. In the present study miR‑590‑5p expression was poorly expressed in OS samples and cell lines when compared with that observed in normal cells. In addition, overexpression of miR‑590‑5p significantly reduced the proliferation, migration and invasion of SAOS2 and U2OS cells in vitro, as well as inhibiting tumor sizes in vivo...
June 15, 2018: Molecular Medicine Reports
R Colomer, I Aranda-López, J Albanell, T García-Caballero, E Ciruelos, M Á López-García, J Cortés, F Rojo, M Martín, J Palacios-Calvo
On page 5 of the article, in the last paragraph of the section "Prognostic genetic platforms: molecular phenotypes and translation to the clinic" a relevant discrepancy between the text and Table 1 could be misunderstood, therefore the paragraph was corrected.
June 18, 2018: Clinical & Translational Oncology
L de la Cruz-Merino, N Palazón-Carrión, F Henao-Carrasco, E Nogales-Fernández, M Álamo-de la Gala, A Vallejo-Benítez, M Chiesa, V Sánchez-Margalet
Immunology and immunotherapy of cancer is an expanding field in oncology, with recent great achievements obtained through the new successful approaches implemented to circumvent immune evasion, which is undoubtedly considered a novel hallmark of cancer. Translational research in this topic has revealed targets that can be modulated in the clinical setting with new compounds and strategies. Like most of the tumors, breast cancer is considered a complex and heterogeneous disease in which host immune responses have been also recently demonstrated of critical relevance...
June 18, 2018: Clinical & Translational Oncology
Evelyne Gineyts, Nicolas Bonnet, Cindy Bertholon, Marjorie Millet, Aurélie Pagnon-Minot, Olivier Borel, Sandra Geraci, Edith Bonnelye, Martine Croset, Ali Suhail, Cristina Truica, Nicholas Lamparella, Kim Leitzel, Daniel Hartmann, Roland Chapurlat, Allan Lipton, Patrick Garnero, Serge Ferrari, Philippe Clézardin, Jean-Charles Rousseau
Periostin is an extracellular matrix protein that actively contributes to tumor progression and metastasis. Here, we hypothesized that it could be a marker of bone metastasis formation. To address this question, we used two polyclonal antibodies directed against the whole molecule or its C-terminal domain to explore the expression of intact and truncated forms of periostin in the serum and tissues (lung, heart, bone) of wild-type and periostin-deficient mice. In normal bones, periostin was expressed in the periosteum and specific periostin proteolytic fragments were found in bones, but not in soft tissues...
June 18, 2018: Calcified Tissue International
Jose G Bazan, Lonika Majithia, Allison M Quick, Jessica L Wobb, Alicia M Terando, Doreen M Agnese, William Farrar, Julia R White
PURPOSE: A meta-analysis of 22 randomized trials accrued from 1964 to 1986 demonstrated significantly higher rates of locoregional failure (LRF) and breast-cancer mortality in women with 1-3 positive nodes without postmastectomy radiotherapy (PMRT) after mastectomy (mast.). Recent data demonstrate that PMRT reduces distant metastases (DM) in women with pN1 disease. The challenge today is whether all patients with pathologic T1-2pN1 disease have similar substantial LRF/DM risk that routinely warrants PMRT...
June 18, 2018: Annals of Surgical Oncology
Qian Lu, Lu Dong, Ivan H C Wu, Jin You, Jialing Huang, Yan Hu
BACKGROUND: Expressive writing interventions are shown to confer physical and psychological benefits for Caucasian cancer survivors. This study evaluated the health benefits of an expressive writing intervention among breast cancer patients in mainland China. METHODS: Stage I-III Chinese breast cancer survivors undergoing chemotherapy were recruited in Shanghai, China. They (n = 90) were randomly assigned to one of three conditions: a positive thinking group (PTC) to write about the positive aspects of their cancer experience; a self-regulation condition (SRC) to write about their stress and coping efforts, deepest feelings, and positive aspects of their cancer experience; or a cancer-fact group (CFC) to write about facts relevant to their cancer experience...
June 18, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
Jonathan Hernández-Capistrán, Jorge F Martínez-Carballido, Roberto Rosas-Romero
Early automatic breast cancer detection from mammograms is based on the extraction of lesions, known as microcalcifications (MCs). This paper proposes a new and simple system for microcalcification detection to assist in early breast cancer detection. This work uses the two most recognized public mammogram databases, MIAS and DDSM. We are introducing a MC detection method based on (1) Beucher gradient for detection of regions of interest (ROIs), (2) an annulus model for extraction of few and effective features from candidates to MCs, and (3) one classification stage with two different classifiers, k Nearest Neighbor (KNN) and Support Vector Machine (SVM)...
June 18, 2018: Journal of Medical Systems
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"